On‐line solid‐phase extraction LC‐MS/MS for the determination of Ac‐SDKP peptide in human plasma from hemodialysis patients
Authors:
- 19 April 2011
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 26 (2) , 137-141
Abstract
We developed a high‐throughput method based on on‐line solid‐phase extraction liquid chromatography tandem mass spectrometry (SPE‐LC‐MS/MS) to determine N‐terminal thymosin‐β fragment peptide (N‐acetyl‐seryl‐aspartyl‐lysyl‐proline, Ac‐SDKP) in human plasma samples. Quantification of Ac‐SDKP was performed using direct injection for on‐line SPE based on C18, reversed‐phase LC separation and stable isotope dilution electrospray ionization‐MS/MS in multiple reaction‐monitoring (MRM) mode. The Ac‐SDKP‐13C6, 15N2 (m/z 496 → 137) was synthesized for the internal standard. The MRM ion for Ac‐SDKP was m/z 488 → 129 (quantitative ion)/226. The limit of detection and lower limit of quantitation were 0.05 and 0.1 ng/mL in standard solution, respectively. Recovery values were 98.3–100.4% with inter‐day (relative standard deviation, RSD, 0.4–14.1%) and intra‐day (RSD, 0.8–19.7%) assays. This method was applied to the measurement of Ac‐SDKP levels in plasma from hemodialyzed subjects. Concentrations were 0.59 ± 0.23 ng/mL (pre‐hemodialyzed subjects, n = 9) and 0.44 ± 0.19 ng/mL (post‐hemodialyzed subjects, n = 9). All plasma Ac‐SDKP levels were decreased by dialysis. Thus, plasma Ac‐SDKP was decreased through dialysis in chronic kidney disease. The findings in this study will be useful for the treatment of anemia in chronic kidney disease with dialysis. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Thymosin β4and its posttranslational modificationsAnnals of the New York Academy of Sciences, 2010
- Overexpression of the natural tetrapeptide acetyl‐N‐ser‐asp‐lys‐pro derived from thymosin β4 in neoplastic diseasesAnnals of the New York Academy of Sciences, 2010
- Biological activities of thymosin ß 4 defined by active sites in short peptide sequencesThe FASEB Journal, 2010
- Peptidomics of Prolyl Endopeptidase in the Central Nervous SystemBiochemistry, 2009
- Assessment of Patients’ and Physicians’ Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) StudyDiabetes Care, 2006
- Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart FailureCirculation, 2005
- Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKPHypertension, 2004
- DEVELOPMENT OF AN ENZYME IMMUNOASSAY FOR A STABLE AMIDATED ANALOG OF THE HEMOREGULATORY PEPTIDE ACETYL-SER-ASP-LYS-PROJournal of Immunoassay and Immunochemistry, 2001
- High Plasma Level ofN-Acetyl-Seryl-Aspartyl-Lysyl-ProlineHypertension, 1997
- Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassayBiochemical and Biophysical Research Communications, 1990